• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal & Metabolism
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality
      • Environment, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Chinese family embracing exercise and the outdoors
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Patient Perspectives

AI Nurse evolving for health failure patients in China

Improved versions of our new digital platform for heart failure disease management in China have been developed since April, 2020 rollout.

Jan 07, 2021

Dozens of improved versions of our new digital platform for heart failure disease management in China have been developed since roll-out a few months ago.

Why? Because the digital product team in Novartis China has quickly learned from user feedback – evolved its approach to Health Care Professionals (HCPs) - and rapidly developed product enhancements.

Realizing the onboarding experience for patients was too complicated in a busy hospital environment – and patients were struggling to manage their condition in lockdown during the COVID-19 pandemic, the AI Nurse product team made it easier to start a patient on the platform, incorporated COVID-19 risk mitigation, and boosted training support for doctors and nurses.

AI Nurse is one of the Novartis global digital ‘bold move’ projects, developed through the strategic partnership of Novartis and Tencent, once of the world’s largest internet companies.

“I don’t think Tencent had ever had to develop so many iterations of a new product before,” said Christian Hein, Novartis Executive Director, Digital Products, “but this digital AI Nurse team has been the perfect example of an agile digital team in action – trying, learning and changing course as needed."

“They’ve followed the number one rule of any start-up – listen to your customers – and make it as easy as possible to use a new product you’ve developed.”

AI Nurse training for hospital nurses

The healthcare challenge

AI Nurse is an AI-enabled disease management tool, created to tackle a vast healthcare challenge:

  • China has 13.5 million patients with heart failure
  • Heart disease is the leading cause of death – 2 out of every 3 deaths
  • An aging population means morbidity and mortality are increasing
  • With no established primary care structure, prescription adherence is poor once patients leave hospital. Many patients are re-hospitalized several times within a year.

The digital solution

AI Nurse on WeChat

The AI Nurse digital health platform was developed for physicians and patients to better manage heart failure, improve prognosis and reduce hospitalization.

Since official rollout began in July, 300+ China’s leading hospitals in over 100 cities have started to embed the digital solution in standard discharge protocol, with over 25 000 patients recruited. AI Nurse helps patients track their health at home on a daily basis, and interact with their hospital-based HCPs.

However, there were challenges with the initial roll-out:

  • In-hospital patient recruitment was hit by COVID-19. With many regions in lockdown, fewer heart failure patients were going to hospital.
  • The onboarding process - involving simultaneous doctor, nurse and patient involvement - proved too complex in a busy hospital environment.
  • The novelty of the approach – a disease management platform for elderly patients – needed more explaining than envisaged

Fast course correction

To meet the recruitment challenges, the AI Nurse team:

  • Made it far easier to onboard the patient – reducing the time needed from ~25mins to ~3.5mins
  • Accelerated the hospital rollout speed from previously planned 50 hospitals per month to 200+ hospitals in the 1st month to expand access
  • Developed ‘AI Nurse Lite’ – a faster, less complex patient onboarding system for outpatients
  • Provided in-hospital training sessions for doctors and nurses, including role play, plus virtual technical support

The AI Nurse team also acted quickly to remodel the platform for COVID-19. AI Nurse was given a ‘pandemic make-over’ to enable patients to better manage their heart failure under lockdown. Basic facts on COVID-19 were embedded, as was a quick guide to self-detection and up-to-date guidance on mitigating virus risk.

Now the team is busy developing a self-service enrolment version – for patients to enroll themselves online.

“This was a first for us,” said Stella Ji, Head of Business Transformation Enabler & Digital, Novartis China. “Through the collaboration with the Beijing Society of Cardiology, the whole healthcare ecosystem was activated - from top national KOLs, to hospital heads, then department heads, then physicians, and finally, nurses, who are in charge of patient recruitment."

“Part of the success comes from delivering different value propositions to each HCP type – understanding their pain points and showing how AI Nurse would help. We’re not only introducing a new digital platform but a whole new process – a new way of benefiting patients.”

To find out more about our digital strategy, click here.

Related story

AI Nurse set to transform standards of care for heart failure patients in China

Shareline

Read about Novartis’s AI Nurse digital health platform, developed for physicians and patients to better manage heart failure.
Tweet Tweetpopo
Tags: 
Chronic Illness, Digital, Heart Failure
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Couple looking a digital devices outside
Patient Perspectives

Digital innovation looks set to dominate the 2021 healthcare agenda

A woman, accompanied by her caregiver, shares her experiences with a doctor.
Patient Perspectives

Turning the sound up on patient voices in lung cancer research and development

Patient living with chronic myeloid leukemia advocates for herself
Patient Perspectives

Speaking Up in CML

You are here

  1. Home ›
  2. Stories ›
  3. Patient Perspectives

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.